- Home
- EDIT vs ALGS Comparison
EDIT vs ALGS Comparison
Compare EDIT & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- ALGS
- Stock Information
- Founded
- EDIT 2013
- ALGS 2018
- Country
- EDIT United States
- ALGS United States
- Employees
- EDIT N/A
- ALGS N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- EDIT Health Care
- ALGS Health Care
- Exchange
- EDIT Nasdaq
- ALGS Nasdaq
- Market Cap
- EDIT 108.1M
- ALGS 118.8M
- IPO Year
- EDIT 2016
- ALGS 2020
- Fundamental
- Price
- EDIT $1.92
- ALGS $18.63
- Analyst Decision
- EDIT Buy
- ALGS Strong Buy
- Analyst Count
- EDIT 14
- ALGS 1
- Target Price
- EDIT $8.08
- ALGS $75.00
- AVG Volume (30 Days)
- EDIT 5.8M
- ALGS 268.0K
- Earning Date
- EDIT 03-03-2025
- ALGS 03-11-2025
- Dividend Yield
- EDIT N/A
- ALGS N/A
- EPS Growth
- EDIT N/A
- ALGS N/A
- EPS
- EDIT N/A
- ALGS N/A
- Revenue
- EDIT $61,759,000.00
- ALGS $5,997,000.00
- Revenue This Year
- EDIT N/A
- ALGS N/A
- Revenue Next Year
- EDIT N/A
- ALGS N/A
- P/E Ratio
- EDIT N/A
- ALGS N/A
- Revenue Growth
- EDIT 150.95
- ALGS N/A
- 52 Week Low
- EDIT $1.12
- ALGS $6.76
- 52 Week High
- EDIT $11.58
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- EDIT 55.72
- ALGS 33.33
- Support Level
- EDIT $1.12
- ALGS $20.12
- Resistance Level
- EDIT $3.30
- ALGS $24.33
- Average True Range (ATR)
- EDIT 0.30
- ALGS 2.67
- MACD
- EDIT 0.12
- ALGS -0.38
- Stochastic Oscillator
- EDIT 36.70
- ALGS 4.38
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.